AMAG Reports 2017 Financial Results and Company Update

Pharmaceutical Investing

AMAG Pharmaceuticals (NASDAQ:AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: Total GAAP revenue for the full year of 2017 increased approximately 15% to $609.9 million, driven by increased sales growth across AMAG’s portfolio, which includes Makena® (hydroxyprogesterone caproate injection), Feraheme® …

AMAG Pharmaceuticals (NASDAQ:AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

Total GAAP revenue for the full year of 2017 increased approximately 15% to $609.9 million, driven by increased sales growth across AMAG’s portfolio, which includes Makena® (hydroxyprogesterone caproate injection), Feraheme® (ferumoxytol injection) and Cord Blood Registry (CBR), as well as the addition of Intrarosa® (prasterone) to the company’s portfolio and subsequent launch in July 2017. The company reported a GAAP operating loss of $293.3 million in 2017, due primarily to a third quarter non-cash accounting charge, and non-GAAP adjusted EBITDA of $230.1 million in 2017.¹

Click here to read the full press release.

amag pharmaceuticals financial results injection intrarosa Pharmaceutical Investing